Revenue, 2025

USD 271.05 Million

Forecast, 2035

USD 510.71 Million

CAGR, 2026-2035

6.54%

Report Coverage

Global

Cardiac Cannula Market Trends for 2026

The global cardiac cannula market size was estimated at USD 271.05 million in 2025 and is predicted to increase from USD 288.78 million in 2026 to approximately USD 510.71 million by 2035, expanding at a CAGR of 6.54% from 2026 to 2035.

The worldwide rising cases of CVD, chronic lung diseases, especially in the Asia region is driving the demand for these advanced cannulas. However, researchers are actively investigating biocompatible materials to reduce the arising body issues.

Key Takeaways

• Cardiac cannula sector pushed the market to USD 288.78 million by 2026.
• Long-term projections show USD 510.71 million valuation by 2035.
• Growth is expected at a steady CAGR of 6.54% in between 2026 to 2035.
• North America registered dominance in the market in 2025.
• Asia Pacific is expected to witness rapid expansion during the forecast period.
• By product type, the arterial cannulas segment led the market in 2025.
• By product type, the specialty cannulas segment is expected to be the fastest-growing in the studied years.
• By age group, the adults segment dominated the cardiac cannula market in 2025.
• By age group, the pediatric segment is expected to grow at a rapid CAGR during 2026-2035.
• By size, the 11 Fr – 22 Fr segment was dominant in the market in 2025 and is expected to grow fastest in the upcoming years.
• By application, the cardiopulmonary bypass (CPB) segment held the largest share of the market in 2025.
• By application, the extracorporeal membrane oxygenation (ECMO) segment is expected to grow rapidly during 2026-2035.

What are the Ongoing Transformations in Cardiac Cannula?

Primarily, the cardiac cannula market covers a thin, flexible tube inserted into veins, arteries/heart chambers to transfer blood to a heart-lung machine or facilitate extracorporeal life support (ECMO) during surgery.  To drive overall market progression, the leading firms are emphasizing minimal invasiveness, promoting self-expanding venous SmartCannula designs for robust drainage, anti-thrombogenic coatings, & also 3D-printed, patient-specific prototypes to enhance flow & lower complexity.

What are the Extensive AI Advances in the Cardiac Cannula Market?

An immersive study has shown that a CT-driven, AI-assisted, preprocedural simulation for guiding-catheter selection lowers procedural time from 91.8 to 68.5 minutes, & reduces catheter-related events. Alongside, more sophisticated AI solutions support automatic detection of vessel lumen and boundaries, with high agreement with human experts in plaque analysis. Whereas CorPath GRX is enabling remote navigation, with features like ‘Rotate on Retract’ that improve wire rotation & reduce both procedure time and radiation exposure for clinicians.

Trends & Future Outlook of the Cardiac Cannula Market

Fostering Minimally Invasive & Percutaneous Procedures

The globe is increasingly stepping towards tiny, more flexible cannulae that allow for femoral artery access for cardiopulmonary bypass (CPB) & minimal chest incisions.

Implementing Balloon-Inflatable Venous Cannulae

An innovative, heparin-coated venous cannulae is featuring combined inflatable balloons to gain full caval occlusion from within, which will lower the need for surgical dissection & snares.

Looking for Bioresorbable Materials

Nowadays, researchers are putting efforts into discovering advanced bioresorbable cannulas that safely degrade within 12–18 months & focuses on omitting the need for removal surgeries & reducing long-term foreign body concerns.

Quick Facts Table

Segmentation Analysis

Product Type Insights

Which Product Type Led the Cardiac Cannula Market in 2025?

In 2025, the arterial cannulas segment captured a major revenue share of the market. A key driver is a massive rise in cases of cardiac, vascular, and chronic diseases, which need frequent surgeries & continuous, long-term monitoring, and finally raise the demand for reliable arterial cannulas. Prospective studies are focusing on the development of anti-thrombogenic coatings, kink-resistant, flexible polyurethane materials, & low-profile, tapered tips for vessel protection. 

Specialty Cannulas

Moreover, the specialty cannulas segment is anticipated to expand fastest in the coming era. Specifically, globally increasing demand for single-use or disposable products to mitigate infections, with a growing need for specialized, kink-resistant designs in complex, long-duration procedures, such as ECMO are impacting the segmental growth. Emerging trends include the recent FDA approval for the SmartFlow Neuro Cannula for targeted, deep-brain delivery of gene therapies (KEBILIDI), and also blunt-tipped microcannulas for dermal fillers and facial volumizing.

Age Group Insights

How did the Adults Segment Dominate the Cardiac Cannula Market in 2025?

The adults segment led with the largest share of the market in 2025. Across the globe, the 60+ age group is highly affected by CVDs, with greater demand for ECMO/cardiopulmonary bypass, which fuels the demand for advanced cannula during surgeries. For the robust results, they are widely adopting smaller, high-performance, & flexible cannulas for robotic-assisted cardiac surgeries & percutaneous interventions, which further lowers trauma & recovery time.

Pediatric

On the other hand, the pediatric segment is estimated to show rapid growth As per the survey, nearly 1.35 million infants are diagnosed with CHD each year, with 90% in regions with restricted, improper, or no care. To overcome these arising risks, diverse public & private investments in specialized children’s hospitals and cardiac catheterization labs, especially in the Asia-Pacific region.

Size Insights

Which Size Led the Cardiac Cannula Market in 2025?

In 2025, the 11 Fr – 22 Fr segment dominated the market & is predicted to expand at the fastest CAGR. This is mainly propelled by the wider adoption in pediatric, neonatal, & minimally invasive adult procedures, which facilitate optimal venous drainage & arterial perfusion for patients with tiny vessels, typically assisting body weights ranging from 3 to 40+ kg. Further innovations are encouraging the breakthroughs in polyurethane materials, bi-directional flow designs for peripheral access, & modern, wire-reinforced structures to maintain increased flow rates.

Application Insights

Why did the Cardiopulmonary Bypass (CPB) Segment Dominate the Market in 2025?

In 2025, the cardiopulmonary bypass (CPB) segment captured the dominating share of the cardiac cannula market. The use of a cardiac cannula in these instances allows stable, low-resistance, & secure blood flow, with minimal vessel damage & also enables cerebral perfusion in complex cases. The market has been exploring novel designs, including the optiCAN, which possesses a helical outflow & jet-splitting dispersion tip, and emphasizes restoring physiological cerebral flow & lowering embolic concerns.

Extracorporeal Membrane Oxygenation (ECMO)

In the future, the extracorporeal membrane oxygenation (ECMO) segment is anticipated to witness rapid expansion. A particular catalyst is the accelerating incidence of chronic obstructive pulmonary disease (COPD), heart failure, & infections, such as influenza or COVID-19, which demand modern life support. However, researchers are actively focused on implementing ultrasound-guided, percutaneous insertion to minimize vascular complications & allow for awake-ECMO mobilization.

Regional Insights

What Made North America Dominant in the Market in 2025?

North America dominated the cardiac cannula market in 2025, due to the rising cases of CVD, the geriatric population, and a center of well-established healthcare infrastructure. The region is increasingly leveraging extracorporeal membrane oxygenation (ECMO) for vital care, specifically following the growth in respiratory & cardiac failures.

For instance,

• In February 2026, Pulse Biosciences, Inc. presented late-breaking clinical data from the nPulse Cardiac Catheter first-in-human feasibility study, which has shown successful treatment of atrial fibrillation in 150 patients with faster procedure times & lowered adverse effects.

U.S. Market Trends

However, the U.S. market held the largest share, as it is putting efforts into developing novel arterial cannulas that are being united with sensors to offer real-time monitoring of oxygen levels, pressure, & blood flow.

For instance,

• In February 2026, BioCardia is closer than ever to achieving the US FDA authorization for an innovative catheter capable of delivering cell & gene therapies directly into the heart.  

Spurring Minimally Invasive Procedures & Local Production is Fueling the Asia Pacific

During the prospective period, the Asia Pacific is predicted to witness the fastest expansion in the cardiac cannula market. The region is highly transforming the adoption of minimally invasive techniques, like smaller, specialized cannulas for MICS-CABG & robotic-assisted procedures, with a substantial focus on domestic manufacturing of specialized catheters and valves within China & India.

Especially, many Indian manufacturers, such as Meril Life Sciences, are majorly expanding with locally established, affordable alternatives, like the MyVal THV series for transcatheter valve replacement. India is widely utilizing single-use, high-precision devices to boost patient safety & expedite recovery.

Cardiac Cannula Market- Supply Chain Analysis

R&D

• This prominently covers explaining clinical requirements, material selection, design & simulation, prototyping, and strong testing.
• Key Players: Medtronic, Edwards Lifesciences, Terumo Corporation, etc.

Clinical Trials & Regulatory Approvals

• Leaders are following the evaluation of safety & efficacy, typically leveraging prospective, multi-center, randomized clinical trials with substantial approvals, like FDA Class II/III, CE Mark, and PMDA in Japan.
• Key Players: IPERF SAS, Mayo Clinic, Indonesia University, etc.

Patient Support & Services

• They primarily provide 30-day CentriMag acute support, HeartMate remote monitoring, & specialized catheter training for clinicians to enhance patient results. 
• Key Players: Abbott Laboratories, Boston Scientific, LivaNova PLC, etc.

Key Players' Offerings in the Cardiac Cannula Market

SWOT Analysis

Strengths

• Majorly, central arterial cannulae allow greater flow rates for CPB, while venous cannulae facilitate efficient drainage & decompression of the heart.
• Whereas specialized cannulae offer consistent, efficient cooling and accurate, direct delivery of cardioplegic solutions to the heart muscle.

Weaknesses

• Increases risk of hematoma, femoral artery dissection, pseudoaneurysm, and arteriovenous fistula is impacting the global adoption.
• In some cases, an acute type A aortic dissection, it can result in false lumen perfusion.

Opportunities

• In the advanced cannulas, incorporation of sensors for continuous tracking of pressure, flow, and oxygen levels will bolster precision in critical procedures, including ECMO.
• Research activities are fostering biocompatible, durable, and anti-clotting materials to minimize complications.

Threats

• Nowadays, manufacturers are facing high-stakes challenges from product defects, which lead to FDA recalls & subsequent legal actions from injured patients.
• Certain studies demonstrated that cardiac catheters can release microplastics (MPs) into the bloodstream, which can stimulate regulatory scrutiny & need companies to invest in emerging, safer, non-plastic options.

What are the Key Developments in the Cardiac Cannula Market?

• In October 2025, Cagent Vascular commercially launched the Serranator PTA Serration Balloon Catheter in 7.0 mm and 8.0 mm diameters.
• In August 2025, India unveiled its first motorized TAVR delivery system, the VitaFlow Liberty from MicroPort, which raises outcomes for complex bicuspid aortic valves.
• In May 2025, Abbott introduced the TactiFlex Sensor-Enabled Ablation Catheter, the world’s first ablation catheter, with a flexible tip combined with contact force technology.

Segments Covered in the Report

By Product Type

• Cardioplegia Cannulas
• Arterial Cannulas
• Venous Cannulas
• Specialty Cannulas

By Age Group

• Pediatric
• Adults

By Size

• 4 Fr – 7 Fr
• 8 Fr – 10 Fr
• 11 Fr – 22 Fr
• 23 Fr – 36 Fr
• 36+ Fr

By Application

• Minimally Invasive & Robotic Surgery (MICS)
• Cardiopulmonary Bypass (CPB)
• Extracorporeal Membrane Oxygenation (ECMO)

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA